STING1 and neoplasm: Intriguingly, in the bone cancer pain model which may involve both inflammatory pain and neuropathic pain, systemic administration of STING activator DMXAA attenuated the measures of spontaneous and ongoing pain; the analgesic effect may attribute to the increasing proportion of CD8+ T cells in the bone marrow tumor microenvironment (Donnelly et al., 2021).